traffic analytics Rx&D - Canada's Research Based Pharmaceutical Companies
  Rx&DAbout Rx&DPharmaceutical Community
PublicationsMedia CentreStakeholders & PartnershipsMember's Login
 
 
 
  Forgot Password?
  Account Application
Rx&D HomeFrançaisContact Us
Useful LinksSite Map
  Pharmaceutical Community

Code of Conduct - Question & Answers

2. Advertising & Information Dissemination - January 2006

Question 1:
Is email acceptable as a means of announcing new products to the Special Audience (Drug Info Centers, Poison Control Centers, etc.) as outlined in Sections 2.3.2 and 2.3.3 of the Rx&D Code?

The wording of the Code seems clear; however, it may simply that the Code has not been updated to reflect new way of communications. We believe that the spirit of the Code would be achieved if we follow the following process:

1. We now we have a specific contact from every organization on the Special Audience mailing list. Before this, many of the organizations in this Special Audience only had a general mailing address for these kinds of notices.

2. Within the last two months, the mailing supplier, has called every organization on the Rx&D mailing list and secured the appropriate contact name and email address. The supplier asked specifically for the name of the person that expects to receive these kinds of notices.

3.The supplier will put in place a 2nd procedure for emails that bounce back. If that happens, the supplier will then follow up with a fax or a notice by regular mail.

4.We will be attaching a delivery receipt to each message to make sure it transmits to the final destination.

5.Each email will also include a link that the recipient will be asked to click on to confirm that they have read our message. This is the equivalent of the "read receipt request" utility in MS Outlook, which does not work with messages sent outside of a network.

Response:
It is understood that all member companies will take whatever internal measures needed to communicate related product information within agreed upon timelines. All written communication means, (e-mail, fax, courier) are acceptable and must follow the member company's internal processes. Irrespective of the method of written method of communication employed, member companies should maintain complete and accurate records of such sensitive correspondence and have a tracking mechanism to ensure its receipt.

Your suggested process may serve as a good internal reminder for communicating with e-mail.

Revised: April, 2006
 
 
Back to top

Home | About Rx&D | Pharmaceutical Community | Publications | Media Centre | Stakeholders & Partnerships
Useful Links | Français | Contact Us | Site Map

55 Metcalfe Street, Suite 1220, Ottawa, Ontario K1P 6L5
Tel.: (613) 236-0455 Reception Fax: (613) 236-6756
Strategic Affairs & Communications Fax: (613) 236-6861
Federal Affairs Fax: (613) 236-7919
© 2007 Rx&D Terms and Conditions of Use
All Rights Reserved